Identity
- Trade Name
- MIRACLE-EAR FDA UDI
- Generic Name
- Tinnitus masking application software FDA UDI
- Model / Reference
- MIRACLE-EAR BLISS 3 RIC RT FDA UDI
Identifiers
- Primary DI / UDI-DI
- 00842318198525 FDA UDI
- FDA Product Code
- OSM FDA UDIKLW FDA UDI
- GMDN Term
- Tinnitus masking application software FDA UDI
Classification
- Device Class
- Class II FDA UDI
- Regulation Number
- 874.3305 FDA UDI874.3400 FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
Yes
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
No
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
No
FDA UDI
Lot / Batch Number
No
FDA UDI
Serial Number
Yes
FDA UDI
Expiration Date
No
FDA UDI
Manufacturing Date
Yes
FDA UDI
MR Unsafe FDA UDI
Category: Air-conduction hearing aid, receiver-in-canalTinnitus masking application software
Miracle-Ear by Starkey Laboratories Inc. — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Tinnitus masking application software.
- NUEAR — Starkey Laboratories Inc. · Class II
- AMPLIFON — Starkey Laboratories Inc. · Class II
- AUDIBEL — Starkey Laboratories Inc. · Class II
- NUEAR — Starkey Laboratories Inc. · Class II
- AMPLIFON — Starkey Laboratories Inc. · Class II
- AUDIGY — Starkey Laboratories Inc. · Class II
- AUDIOSYNC — Starkey Laboratories Inc. · Class II
- AUDIBEL — Starkey Laboratories Inc. · Class II
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class II | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Starkey Laboratories Inc.
Sources (1)
- FDA UDI 6e0b4a3b-6e21-4d97-b527-29e692d7eeb4 33 fields · synced Jun 9, 2026